Raymond James Financial
MLYS icon

Raymond James Financial’s Mineralys Therapeutics MLYS Stock Holding History

Raymond James Financial’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$669K Sell
24,677
-297
-1% -$8.71K ﹤0.01% 4148
2025
Q4 		$906K Buy
+24,974
New +$1M ﹤0.01% 3846
2025
Q3 		– Sell
-141
Closed -$1.91K – 6029
2025
Q2 		$1.91K Buy
+141
New +$2.04K ﹤0.01% 6422

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Raymond James Financial's MLYS Position: Q1 2026 in Review

Raymond James Financial reduced its Mineralys Therapeutics (MLYS) stake by 1.2% in Q1 2026, selling an estimated $8.71K and leaving 24,677 shares worth $669K. The position accounts for ﹤0.01% of the portfolio, ranked #4148.

Raymond James Financial first reported a position in MLYS in Q2 2025 and has held it in 3 quarters since. The position peaked at $906K in Q4 2025. 214 funds tracked by Wall St. Rank hold MLYS as of Q1 2026.

  • Raymond James Financial held 24,677 shares of Mineralys Therapeutics worth $669K as of Q1 2026.
  • Raymond James Financial sold 297 Mineralys Therapeutics shares in Q1 2026, an estimated $8.71K.
  • Mineralys Therapeutics made up ﹤0.01% of Raymond James Financial's portfolio in Q1 2026, its #4148 holding.
  • Raymond James Financial first reported a position in Mineralys Therapeutics in Q2 2025 and has held it in 3 quarters since.
  • Raymond James Financial's Mineralys Therapeutics position peaked at $906K in Q4 2025.
  • 214 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.